Ha Kung Wong

Partner
Wong Ha kung
Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation as well as intellectual property transactions and contract negotiations for mergers, acquisitions, vendor agreements and collaborations in pharmaceuticals, biologics, chemistry and medical devices. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, ADHD medications, injectable microspheres, RNAi products and other pharmaceuticals. Ha Kung also has extensive experience with inter partes review, post grant review, intellectual property counseling, pre-suit investigations, licensing and due diligence, including patent strength and freedom-to-operate analyses.

Experience

Representative Matters

  • Represented Alkermes against Luye Pharma on a patent related to injectable microsphere formulations for treatment of a variety of indications, including schizophrenia
  • Represented Allergan against Wilshire, Somerset, and Aurobindo on patents related to ophthalmic formulations of alcaftadine, for once-daily treatment of allergic conjunctivitis
  • Represented Alnylam against Silence Therapeutics on patents related to RNAi technology
  • Represented Allergan against Prinston Pharmaceutical on patents related to tablet formulations of nebivolol hydrochloride and valsartan to treat hypertension
  • Represented AstraZeneca against Andrx, Genpharm, Dr. Reddy, and Schwartz Pharma on patents related to omeprazole and its formulations
  • Represented Bristol-Myers Squibb against the Regents of the University of Michigan, Repligen Corp., and ZymoGenetics on patents related to synthetic fusion proteins for regulating the immune system
  • Represented UCB against Mylan, Dr. Reddy, Sandoz, and Cobalt on patents related to levetiracetam, a leading epilepsy medicine
  • Represented GlaxoSmithKline against Barr Pharmaceuticals on patents related to dutasteride, a leading BPH drug
  • Represented UCB and Celltech against KV Pharmaceutical on patents related to methylphenidate hydrochloride, an ADHD medicine

Representative Clients

  • Alkermes
  • Allergan
  • Alnylam
  • Bill & Melinda Gates Foundation and Gates MRI
  • Materia
  • Stemline
  • UCB

Insights

Credentials
+

Education

  • J.D. cum laude University of Notre Dame Law School 1999
  • B.S. Chemistry High Distinction University of Illinois Urbana-Champaign 1996
  • B.S. Biochemistry University of Illinois Urbana-Champaign 1996

Bar Admissions

  • New York

Court Admissions

  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Federal Claims

Recognition
+

  • Recognized as an IP Star in Managing Intellectual Property, 2019
  • Named as an “Elite Boutique Trailblazer,” The National Law Journal, 2017 Inaugural List
  • Recipient, ILO Client Choice Individual Award for Intellectual Property in the United States and New York, 2017
  • Recognized as one of the World’s Leading Patent Practitioners, IAM 1000, 2018
  • Recognized as a “Leading Attorney,” LMG Life Sciences, 2017 - 2018
  • Recognized as a Rising Star in Intellectual Property Litigation, Super Lawyers: New York Metro Edition, 2012 - 2015
  • Included in Legal 500 for Patent Litigation: Full Coverage, 2008, 2009
  • Named a "Furthered 40," Lawline

Community
+

Personal Activities

  • Member, Venable Board
  • Advisory Board Member, Center for Biosimilars